Relationship between oral hypofunction and medical expenditure in older adults in Japan.

This study aimed to analyze the impact of poor oral function on medical expenditures among older adults. We diagnosed oral hypofunction based on dental data obtained from oral health examinations and examined its association with several annual medical expenditures. Compared to individuals without oral hypofunction, those with oral hypofunction incurred higher total, outpatient medical, inpatient medical, dental, dispensing medical, and lifestyle-related medical expenditures.

Factors correlated to oral frailty and number of remaining teeth among 80-year-old population in Japan.

Background: Oral frailty is proposed as a new concept defined as an age-related gradual loss of oral functions accompanied by a decline in cognitive and physical functions in older adults. Additionally, the participants with ≥ 20 remaining teeth are associated with a lower risk of cognitive frailty in older adults. Herein, we aimed to examine the correlations between the high risk of oral frailty and oral conditions or health behavior in community-dwelling 80-year-old adults in Japan.

Dynamic FDG PET/CT for differentiating focal pelvic uptake in patients with gynecological cancer.

This study aimed to evaluate the ability of serial whole-body dynamic PET/CT to differentiate physiological from abnormal F-FDG uptake in the abdomen and pelvis of gynecological cancer patients. We conducted a retrospective study of 61 F-FDG PET/CT examinations for suspected gynecological malignancies or metastases between March 2018 and January 2020. Our protocol included four-phase dynamic whole-body scans.

Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.

Introduction: Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalence of MASLD is increasing worldwide, there is currently no consensus on the efficacy and safety of the drugs used to treat MASLD/metabolic dysfunction-associated steatohepatitis (MASH). Pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, was designed to have higher peroxisome proliferator-activated receptor alfa (PPARα) agonist activity and selectivity than existing PPARα agonists, and in development trials, without increasing creatinine levels, lipid parameters and alanine aminotransferase (ALT) were significantly improved.